07-Jul-16 China's top pricing regulator has launched a round of drug pricing and healthcare financing reform in the latest attempt to improve the nation's public healthcare system. The pricing reform is expected by the end of 2020, by which time financing of all public hospitals will mainly depend on healthcare services and government compensation, rather than markup of drug prices. [image: Inventariando China]

01-Jul-16 Biotechnology is one of seven strategic industries that the Chinese government designated in the 13th Five-Year Plan. "Made in China 2025", an initiative to upgrade industry, also designates biotechnology as a key industry to push economic development. China's bio-pharmaceutical market is expected to reach USD601 bn by 2020. [image: China Daily]

28-Jun-16 Pfizer Inc will invest USD350 mn to build a biotech center in China, the latest in move by pharma industry giants to set up in the world's no.2 drugs market, with the aim of securing faster approvals for products. The facility in Hangzhou - Pfizer's first biotech center in Asia - is expected to be completed by 2018. [image: Reuters / Andrew Kelly]

20-Jun-16 Apollo Hospitals Group and Hainan Ecological Smart City Group, a Chinese industrial park developer, signed an MoU jointly to develop a highly integrated modern healthcare service facility in China's Hainan province. The hospital will have medical, nursing and paramedical colleges attached and will cater to medical tourists from China and other nations, as well as people from Hainan. [image: Indian White Paper]

15-Jun-16 Bricon GmbH, part of China's Naton Medical Group, has acquired the manufacturing site of Zrinski AG in Germany and has re-formed it as Zrinski GmbH. Naton, with more than 3,500 employees, is one of China’s leading medical technology manufacturers. It intends to expand its position in the premium segment of the Chinese market with products “Made in Germany”. [image: Zrinski]